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Effect of Function-EnhancedMesenchymal StemCells
Infected With Decorin-Expressing Adenovirus on
Hepatic Fibrosis
YOON OK JANG,a,b MEE-YON CHO,c CHAE-OK YUN,d SOON KOO BAIK,a,b KYU-SANG PARK,e
SEUNG-KUY CHA,e SEI JIN CHANG,f MOON YOUNG KIM,a YOO LI LIM,a SANG OK KWONa
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ABSTRACT
Bone marrow-derived mesenchymal stem cells (BM-MSCs) are known to have an antifibrotic effect
and could be used as vehicles for targeted gene delivery. Decorin plays a protective role against fibro-
genesis by modulating the degradation of the extracellular matrix. The aim of this study was to de-
termine whether the antifibrotic effect of a combination treatment consisting of BM-MSCs and
decorin on hepatic fibrosis is superior to BM-MSCs alone. The effects of BM-MSCs infected with
decorin-expressing adenovirus (DCN-MSCs) on hepatic fibrosis were examined in a rat model of thi-
oacetamide (TAA)-induced cirrhosis. The effects of infection with decorin-expressing adenovirus and
of incubation with the conditioned medium of DCN-MSCs on transforming growth factor-b (TGF-b)
signalingwere analyzed in immortalizedhumanhepatic stellate cells (HSCs). According to the Laennec
fibrosis scoring system, cirrhotic livers from rats treated with DCN-MSCs exhibited histological im-
provement compared with cirrhotic livers from rats treated with control adenovirus-infected MSCs
(CA-MSCs). DCN-MSC treatment reduced hepatic collagen distribution, lowered the hydroxyproline
content, and rescued liver function impairment in rats with TAA-induced cirrhosis. These protective
effects were more potent with DCN-MSCs than with CA-MSCs. The upregulation of collagen-1,
a-smooth muscle actin (a-SMA), TGF-b1, and Smad3 phosphorylation in cirrhotic livers was pre-
vented by DCN-MSC administration. Intriguingly, medium from cultured DCN-MSCs blocked both
Smad3phosphorylation andexogenous TGF-b1 stimulateda-SMAsynthesis inHSCs. DCN-MSCs exert
strong protective effects against hepatic fibrosis by suppressing TGF-b/Smad signaling. Thus, treat-
ment with DCN-MSCs is a potentially novel and efficient therapeutic approach for patients with in-
tractable cirrhosis. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1247–1256
SIGNIFICANCE
A combination treatment consisting of bone marrow-derived mesenchymal stem cells (BM-MSCs)
anddecorin strongly inhibited theprogressionof thioacetamide-inducedhepatic fibrosis in rats, com-
pared with BM-MSCs alone. Furthermore, the significant inhibitory effect of BM-MSCs infected with
decorin-expressing adenovirus was attributed to suppressing transforming growth factor-b
(TGF-b)/Smad signaling pathway, supported by attenuation of TGF-b1 expression and inhibition
of Smad3 phosphorylation. Therefore, treatmentwith BM-MSCs infectedwith decorin-expressing adeno-
virus could constitute a novel and efficient therapeutic approach for patients with intractable cirrhosis.
INTRODUCTION
Cirrhosis is the end stage of progressive fibrosis,
which is characterized by distortion of the hepatic
architecture and the formation of regenerative
nodules, angiogenesis, and shunts. These symptoms
eventually lead to the loss of liver function and
the development of hepatocellular carcinoma [1–5].
No therapeutic modalities are available for treating
advancedcirrhosis,with theexceptionoforgan trans-
plantation. However, organ transplantation has criti-
cal limitations that have not yet been overcome.
Recently, stem cell transplantation has been
suggested as an alternative therapy for liver dis-
ease. Mesenchymal stem cells (MSCs) have many
practical advantages in regenerativemedicine, in-
cluding their high proliferation rate, multipotent
differentiation capacity, and low immunogenic
properties [6, 7]. In addition, MSCs have the ca-
pacity tomigrate toward sites of injury and tumor
microenvironments. This unique tropism makes
MSCs ideal delivery vehicles for targeted therapy.
We have previously demonstrated that bone
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marrow-derived mesenchymal stem cell (BM-MSC) therapy im-
proves hepatic fibrosis in vitro, in vivo, and in clinical studies [6,
8, 9].
Decorin, a small leucine-rich proteoglycan, is a ubiquitous
component of the extracellular matrix (ECM) [10–13]. Decorin
binds to collagen, retards the formationof collagen fibrils, anddis-
rupts their organization [13]. In addition, decorin blocks signaling
through transforming growth factor-b (TGF-b), a keymediator of
fibrogenesis, and modulates the degradation of the ECM by in-
ducing expression of the matrix metalloproteinase collagenase-
1 [14, 15]. In a human hepatic stellate cell (HSC) line, decorin
has been shown to inhibit TGF-b signaling, downregulate
a-smooth muscle actin (a-SMA) expression, and decrease cell
proliferation [16]. These observations suggest that delivery of
decorin to the liver may attenuate pathogenic fibrosis in patients
with cirrhosis. Of the various gene-delivery systems available,
adenoviruses have been widely used because of their ability to
transfer relatively large genes. However, adenoviruses have
limited utility as a targeted gene-delivery system because they
rapidly disseminate into the surrounding normal tissues and
maintain their biological activity for only short periods of time
in vivo [17].
We hypothesized that BM-MSCs could be used as delivery
vehicles for antifibrotic therapy and that this system would ex-
hibit improved safety and efficacy compared with adenoviral
gene therapy alone. We further hypothesized that BM-MSCs
and decorin-expressing adenovirus may exert a synergistic ef-
fect on the recovery of liver function after fibrotic injury. In this
study, we investigated the effects of BM-MSCs infected with
decorin-expressing adenovirus on hepatic fibrosis in a rat
model of thioacetamide (TAA)-induced cirrhosis. We also ex-
plored the mechanisms underlying their antifibrotic effects in
vitro and in vivo.
MATERIALS AND METHODS
Induction of Hepatic Fibrosis in a Rat Model of
Thioacetamide-Induced Cirrhosis
Seven-week-old male Sprague-Dawley rats (Orient Bio Inc.,
Seongnam, Korea, http://www.orient.co.kr) were maintained
at room temperature (25°C) with a 12-hour/12-hour light/dark
cycle. Rats were given free access to food and water through-
out the 12-week experiment. Hepatic fibrosis was induced in
Sprague-Dawley rats by intraperitoneal injections of TAA
(Sigma-Aldrich, St. Louis, MO, http://www.sigmaaldrich.
com; 300 mg per kilogram of body weight) twice a week
for 12 weeks. All animal experimental procedures and proto-
cols were approved by the Institutional Animal Care and
Use Committee of Yonsei University Wonju College of
Medicine.
Preparation of Decorin-Expressing Adenoviruses and
Human BoneMarrow-DerivedMesenchymal Stem Cells
The preparation of decorin-expressing adenovirus (dE1-k35/
lacZ/DCN) and control adenovirus (dE1-k35/lacZ) was de-
scribed previously [18, 19]. Human BM-MSCs were obtained
from healthy persons who voluntarily donated their bone
marrow (BM) stem cells. Briefly, approximately 10–20 ml of
BM was aspirated from the posterior iliac crest under local
anesthesia. BM mononuclear cells were isolated through
density-gradient centrifugation (Histopaque-1077, Sigma-Aldrich).
Mononuclear cells were plated (2–3 3 105 cells per cm2) in a
75-cm2 flask (Thermo Fisher Scientific Life Sciences, Waltham,
MA, http://www.thermofisher.com) in Dulbecco’s modified
Eagle’s medium (DMEM; Thermo Fisher Scientific Life Sciences)
containing 10% fetal bovine serum (FBS; Thermo Fisher Scien-
tific Life Sciences) and 1% penicillin/streptomycin (Thermo
Fisher Scientific Life Sciences). Cells were cultured at 37°C in
a 5% CO2 atmosphere.When the cultures approached 80% con-
fluence, the cells were harvested by treatment with trypsin/
EDTA (Thermo Fisher Scientific Life Sciences) and replated in
175-cm2 flasks at a density of 4–53 103 cells per cm2. Cells were
serially subcultured to passage four or five before injection. All
procedures and protocols involving human subjects were ap-
proved by the Institutional Review Board of Yonsei University
Wonju Severance Hospital (CR109021) and were conducted
according to the principles of the Declaration of Helsinki. All
participants provided written informed consent before study
participation.
BM-MSC Immunophenotypes and
Differentiation Assays
The immunophenotypes of the BM-MSCs (CD14, CD34, CD45,
CD73, and CD105) were analyzed on the day of adenovirus infec-
tion, and their differentiation potentials were also determined
(osteogenic and adipogenic; Fig. 1). For immunophenotyping,
BM-MSCs were stained with the following antibodies conjugated
to fluorescein isothiocyanate (FITC) or phycoerythrin (PE): CD14-
FITC, CD34-FITC, CD45-FITC, CD73-PE, and CD105-PE (BD Biosci-
ences, San Jose, CA, http://www.bdbiosciences.com). Briefly,
5 3 105 cells were resuspended in 0.2 ml of phosphate-buffered
saline (PBS) and incubated with FITC- or PE-conjugated anti-
bodies for 20 minutes at room temperature. FITC- and PE-
conjugated mouse IgG isotype control antibodies were used
at the same concentrations as the specific primary antibodies.
The fluorescence intensities of the cells were evaluated by flow
cytometry (Epics XL; Beckman Coulter, Miami, FL, https://www.
beckmancoulter.com). Osteogenic differentiation was assessed
by first plating the cells at 23 104 cells per cm2 in six-well plates
and then incubating them for 2–3 weeks in osteogenic medium,
which consisted of DMEM supplemented with 10% FBS, 10 mM
b-glycerophosphate, 1027 M dexamethasone, and 0.2 mM
ascorbic acid (Sigma-Aldrich) [20]. Osteogenic differentiation
was assessed by quantifying the release of p-nitrophenol from
p-nitrophenyl phosphate by alkaline phosphatase [21]. For adi-
pogenic differentiation, BM-MSCs were plated at 23 104 cells
per cm2 in six-well plates and cultured for 1 week; then, differ-
entiation was induced with adipogenic medium (10% FBS,
1 mM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine,
10 mg/ml insulin, and 100 mM indomethacin in high-glucose
DMEM) for an additional 3 weeks. The differentiated cells
were fixed in 4% paraformaldehyde for 10 min, and oil drop-
lets were stained with fresh Oil Red O solution (Sigma-
Aldrich). Only MSCs that met the following criteria were used:
viability greater than 80%; the absence of microbial contami-
nation (bacteria, fungus, virus, or mycoplasma) when tested
3–4 days before administration; CD73 and CD105 expression
in more than 90% of the cells; and the absence of CD14,
CD34, and CD45 in less than 3% of the cells, as assessed by flow
cytometry.
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Administration of BM-MSCs Infected With
Decorin-Expressing Adenovirus in a Rat Model of
Thioacetamide-Induced Cirrhosis
Human BM-MSCs were infected with decorin-expressing adenovirus
(dE1-k35/lacZ/DCN)orcontroladenovirus(dE1-k35/lacZ)atamultiplic-
ity of infection (MOI) of 20. At 48hours after infection, theadenovirus-
infected BM-MSCs were harvested by using trypsin/EDTA.
Animals were randomly allocated into four groups (each
group, n = 18) as follows: group I (G1, sham group); group II
(G2, untreated cirrhotic group), which received the TAA injec-
tions; group III (G3, control adenovirus-infected BM-MSCs treat-
ed group), which received both the TAA injections and the
control adenovirus-infected BM-MSC (CA-MSCs) treatment;
and group IV (G4, decorin-expressing adenovirus-infected
BM-MSC-treated group), which received both the TAA injec-
tions and the decorin-expressing adenovirus-infected BM-
MSCs (DCN-MSCs) treatment. The rats were anesthetized by
intramuscular administration of a mixture of Zoletil (Virbac
Laboratories, Carros, France, https://www.virbac.com) and
Rompun (Bayer Korea, Seoul, Korea, https://www.bayer.co.
kr). By using an aseptic technique, a 1-cm incision was made
caudal to the costal arch on the right flank to expose the right
lobe of the liver. By using a 26-gauge needle, 13 106 CA-MSCs
or 13 106 DCN-MSCs were injected directly into the right lobe
of the liver at 6 and 8 weeks during the 12-week course of TAA
administration (Fig. 2A).After12weeks,bloodsampleswere taken,
and the animals were sacrificed. Liver tissue specimens were col-
lected, fixed, immediately frozen, and storedat280°C for analysis.
Histomorphological and Immunohistochemical Analysis
Five-micrometer-thick sections of paraffin-embedded liver tissue
were prepared and stained with hematoxylin and eosin (H&E),
Masson’s trichrome (MTC), and Picrosirius red. The extent of fi-
brosis was evaluated by using the Laennec fibrosis scoring system
(supplemental online Table 1). In this system, the thickness of
the predominant type of septae in each specimen is chosen, and
the smallest nodule is selected for scoring. A liver pathologist
who was blinded to the data evaluated the extent of fibrosis.
The Laennec fibrosis scoring system was used because it incor-
porates three subclasses of cirrhosis, thereby enabling a more
detailed estimation of the effects of the intervention on fibrosis
[22]. To further assess the effects of each treatment on hepatic
fibrosis, the fibrotic area in each liver samplewas quantified as a
percentage of the total MTC-stained area. The fibrotic area was
assessed in digital photomicrographs by using a computerized
image analysis system (Analysis 3.0, Olympus, Tokyo, Japan,
http://www.olympus-global.com). To quantify the fibrotic area,
fields of visionwere selected randomly at amagnificationof3100.
Picrosirius red staining was also performed to quantify the
total amount of collagen. Five-micrometer-thick sections of
paraffin-embedded liver tissue were deparaffinized, rehy-
drated with distilled water, and stained with a Picrosirius
red staining kit (Polysciences, Warrington, PA, http://www.
polysciences.com) according to the manufacturer’s instruc-
tions. In addition, the amount of collagen (the main compo-
nent of fibrous tissue) was estimated by determining the
percentage of Picrosirius red-stained area out of the total
area. Collagen staining was observed on an Olympus BX51
microscope and quantified by using image analysis software
(IMT i-solution, Vancouver, BC, Canada, http://www.imt-digital.
com). Imageartifacts and structural collagen in the largeportal tracts
andbloodvesselwallswereomittedfromthetotal collagenarea[23].
For immunofluorescence staining, frozen liver sections were
fixed in cold acetone, and nonspecific binding sites were blocked
by incubation in 10% bovine serum for 2 hours at room temper-
ature. Tissue sections were then incubated with antibodies
against decorin (R&D Systems, Minneapolis, MN, https://www.
rndsystems.com) and monoclonal antibodies against a-SMA
Figure 1. Immunophenotypes and differentiation potentials of bone marrow-derived mesenchymal stem cells (BM-MSCs). (A): Immunophe-
notype analysis of the BM-MSCs. The expression levels of various cell surface antigens (CD14, CD34, CD45, CD73, and CD105)were evaluated by
flow cytometry. (B): Alkaline phosphatase staining. BM-MSCs subjected to osteogenic differentiation in osteogenic medium exhibited positive
staining for endogenous alkaline phosphatase activity. In contrast, BM-MSCs incubated in control medium did not exhibit any staining (mag-
nification:3100). (C): Lipid droplet staining. BM-MSCs subjected to adipogenic differentiation in adipogenicmediumexhibited positive staining
for lipid droplets. In contrast, BM-MSCs incubated in control medium did not exhibit any staining (3200). Abbreviations: Diff., differentiation;
FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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(Abcam, Cambridge, MA, http://www.abcam.com) for 1 hour
at room temperature. The slides were washed with PBS and
incubated with Alexa Fluor 488 (Thermo Fisher Scientific Life
Sciences)-conjugated secondary antibodies for 1 hour at room
temperature in the dark. After washing, the slides weremounted
with Vectashield (Vector Laboratories, Burlingame, CA, http://
vectorlabs.com) mounting medium containing 49,6-diamino-2-
phenylindole (DAPI) for counterstaining of nuclei. Fluorescence
images were observed on a laser scanning confocal microscope
(TCS SPE, Leica Microsystems GmbH, Wetzlar, Germany, http://
www2.leicabiosystems.com).
Measurement of Hepatic Hydroxyproline Content
Liver tissue was hydrolyzed with 6 N HCl for 16 hours at 120°C.
The hydrolysates were then cooled, neutralized with 6 N NaOH,
and spunby centrifugation at 13,000g for 10minutes. The super-
natants were supplemented with 7% chloramine T, acetate/
citrate buffer (sodium acetate·3H2O, trisodium citrate·2H2O,
citric acid, and isopropanol). Ehrlich’s solution (dimethylamino-
benzaldehyde with perchloric acid and isopropanol) was then
added, and the reactions were incubated for 35 minutes at
60°C. After cooling, the absorbance of each well was measured
at 560 nm by using an Emax PrecisionMicroplate Reader (Molec-
ularDevices, Sunnyvale, CA, http://www.moleculardevices.com).
The hydroxyproline concentration of each sample was calculated
from a standard curve prepared with hydroxyproline (Sigma-
Aldrich, H5534). Results are expressed as micrograms of hydrox-
yproline per gram of liver tissue.
Biochemical Parameter Analysis
Measurements of alanine transaminase (ALT), aspartate transam-
inase (AST), total bilirubin, and albumin levels were carried out by
using commercially available kits (Asan Pharmaceutical, Seoul,
Korea, http://www.asanpharm.com) according to the manufac-
turer’s instructions.
Figure2. Treatmentwithbonemarrow-derivedMSCs infectedwithdecorin-expressing adenovirus reverses thehistological changesofhepatic
fibrosis. (A): Experimental procedure. Hepatic fibrosiswas induced in Sprague-Dawley rats by intraperitoneal injection of TAA (300mg/kg) twice
a week for 12 weeks. DCN-MSCs or CA-MSCs were injected directly into the right liver lobe at weeks 6 and 8 of the 12-week course of TAA
administration. (B): Immunofluorescence staining of decorin in liver tissue. Decorin staining was observed on the day at which DCN-MSCs were
injected into the fibrotic livers. Nuclei were stainedwith DAPI.Merged immunofluorescence images of decorin (green) and DAPI (blue) staining
are shown. Scale bar = 75mm. (C): Histological analysis was performed by H&E andMTC staining. The untreated cirrhotic group exhibited clear
cirrhosis with broad septum with minute nodules (F4C). The CA-MSC-treated group exhibited cirrhosis with thin septation with rounded con-
tours or visible large nodules (F4A), whereas the DCN-MSC-treated group showed periportal fibrosis (F2) (magnification:3100). Picrosirius red
staining of sections from liver biopsy specimens show the difference in the collagen-stained area (red) between the untreated cirrhotic group
and the DCN-MSC-treated group (magnification:3100). (D): Quantification of the relative Picrosirius red-stained (collagen) areas. Data were
obtained by an image analysis program. (E): Measurement of hepatic hydroxyproline content. A colorimetric assay was used to quantify the
hydroxyproline content of each liver sample. Values are expressed as means6 SDs. pp, p, .01. Abbreviations: CA-MSCs, control adenovirus-
infected mesenchymal stem cells; DAPI, 49,6-diamidino-2-phenylindole; DCN-MSCs, decorin-expressing adenovirus-infected bone marrow-
derived mesenchymal stem cells; H&E, hematoxylin & eosin; MSCs, mesenchymal stem cells; MTC, Masson’s trichrome; TAA, thioacetamide.
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Quantitative Real-Time Polymerase Chain
Reaction Analysis
Total RNA was isolated from liver tissue using TRIzol reagent
(Thermo Fisher Scientific Life Sciences) according to the manu-
facturer’s protocol. RNA purity and concentration were deter-
mined using a spectrophotometer (Ultrospec 2100 pro UV/
Visible, GE Healthcare Life Sciences, Piscataway, NJ, http://
www.gelifesciences.com). cDNA was synthesized from total
RNA (1 mg) by using the GeneAmp RNA polymerase chain reac-
tion (PCR) Kit (Applied Biosystems, Foster City, CA, http://www.
appliedbiosystems.com) with oligo-dT (Applied Biosystems).
Transcript levels were measured by real-time polymerase
chain reaction (PCR) using sequence-specific primers for
TGF-b1 (F: GGA CTC TCC ACC TGC AAG AC, R: GAC TGG CGA
GCC TTA GTT TG), type 1 collagen (F: CAT GTT CAG CTT TGT
GGA CCT, R: GCA GCT GAC TTC AGG GAT GT), and a-SMA (F:
CGA TAG AAC ACG GCA TCA TCA C, R: GCA TAG CCC TCA TAG
ATA GGC A). Amplification reactions contained SYBR Green
PCR Master Mix (Applied Biosystems) and were performed in
an ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems) according to the manufacturer’s instructions.
Data were analyzed by using SDS 2.2.2 software (Applied Bio-
systems). The cycle threshold (Ct) values of the target genes
were normalized to those of the endogenous control gene
(GAPDH; F: AGA CAG CCG CAT CTT CTT GT, R: TGA TGG CAA
CAA TGT CCA CT). Relative changes were calculated by using
the equation 2–DDCt.
Western Blot Analysis
To generate total protein extracts from liver tissue, samples were
homogenized in T-PER protein extraction reagent (Thermo Fisher
Scientific Life Sciences) by using a TissueLyser II apparatus (Qiagen
GmbH, Haan, Germany, http://www.qiagen.com). The resultant ly-
sateswerespunbycentrifugationat13,000rpmfor15minutesat4°
C, and the protein concentrations of the supernatants were deter-
mined by using a protein assay kit (Bio-Rad Laboratories Inc., Her-
cules, CA, http://www.bio-rad.com). A total of 30 mg of each liver
protein extract was electrophoresed on a 10% sodium dodecyl
sulfate-polyacrylamide (SDS-PAGE) gel and then transferred to a
polyvinylidene difluoride (PVDF) membrane (EMDMillipore, Biller-
ica,MA,http://www.millipore.com).Themembraneswereblocked
with 5% skimmilk in Tris-buffered saline containing 0.1% Tween 20
for 1 hour at room temperature, and themembraneswere then in-
cubatedwithprimaryantibodiesat 4°Covernight. The followingpri-
mary antibodies were used: anti-TGF-b1 (Abcam), anti-a-SMA
(Abcam), anti-Smad3 (Cell Signaling Technology, Danvers, MA, ,
http://www.cellsignal.com), and anti-phospho-Smad3 (Cell Signal-
ing Technology). After washing, membranes were incubated with
horseradish peroxidase-conjugated secondary antibodies
against either mouse IgG (Abcam) or rabbit IgG (Cell Signaling
Technology) for 1 hour at room temperature. Immunoreactive
bands were visualized by using an enhanced chemiluminescence
detection kit (GE Healthcare Life Sciences). All membranes were
also probed withb-actin antibodies (Abcam), and the intensity of
each band was normalized to that of b-actin.
Cell Culture
Immortalized human HSCs that were established by retroviral
expression of human telomerase reverse transcriptase were
used for the majority of the in vitro experiments. Characteriza-
tion by immunofluorescence staining of a-SMA revealed a pu-
rity of . 96%. HSCs were plated in a 75-cm2 flask (Thermo
Table 1. Histological stage of hepatic fibrosis
Group Stage 0 Stage 1 Stage 2 Stage 3 Stage 4A Stage 4B Stage 4C Average
Score 0 1 2 3 4 5 6
G1 18 0
G2 1 7 10 5.5
G3 3 7 7 1 3.3
G4 11 5 2 2.5
G1, sham group; G2, untreated cirrhotic group; G3, control adenovirus-infected BM-MSC-treated group; G4, decorin adenovirus-infected
BM-MSC-treated group.
Abbreviations: BM-MSC, bone marrow-derived mesenchymal stem cell; G, group.
Figure 3. Bone marrow-derived mesenchymal stem cells infected
with decorin-expressing adenovirus (DCN-MSCs) ameliorate bio-
chemical indicators of liver injury. Levels of ALT (A), AST (B), total bil-
irubin (C), and albumin (D) after DCN-MSC administration. Values are
expressed as means6 SDs. pp, p, .01. Abbreviations: ALT, alanine
aminotransferase; AST, aspartate aminotransferase.
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Fisher Scientific Life Sciences) with DMEM (Thermo Fisher Sci-
entific Life Sciences) containing 10% FBS (Thermo Fisher Scien-
tific Life Sciences) and 1% penicillin/streptomycin (Thermo
Fisher Scientific Life Sciences), and cultured at 37°C in a
5% CO2 atmosphere.
Expression of a-SMA and Phospho-Smad3 in HSCs
For direct viral infection, human HSCs were plated in a 75-cm2
flask at approximately 70% confluence and then infected with ei-
ther decorin-expressing adenovirus (dE1-k35/lacZ/DCN) or con-
trol adenovirus (dE1-k35/lacZ) at an MOI of 20. At 48 hours
after infection, the infected cellswere treated eitherwith orwith-
out TGF-b1 (R&D Systems). For indirect viral infection, human
BM-MSCs were infected with either decorin-expressing ade-
novirus or control adenovirus at an MOI of 20. At 48 hours af-
ter infection, HSCswere incubatedwith the supernatants from
virus-infected BM-MSCs for 48 hours and treatedwith or with-
out TGF-b1 (R&D Systems). For the analysis of a-SMA protein
levels, HSCs were treated with or without TGF-b1 (1 ng/ml)
for 24 hours. For the analysis of phospho-Smad3 protein lev-
els, HSCs were treated with or without TGF-b1 (1 ng/ml) for
30 minutes.
Statistical Analysis
All values are presented as means6 SDs. Data were analyzed by
the Kruskal-Wallis H test and the Mann-Whitney test using SPSS
software version 20.0 (IBM, Armonk, NY, http://www.ibm.com).
For all analyses, p values , 0.05 were considered statistically
significant.
RESULTS
Validation of BM-MSCs Immunophenotypes and
Differentiation Potentials
The CD14, CD34, CD45, CD73, and CD105 immunophenotypes
of the cells were determined, and osteogenic or adipogenic dif-
ferentiation was induced on the day of adenovirus infection
(Fig. 1). CD73 and CD105 (positive markers of BM-MSCs) were
expressed in more than 98% of the cells, whereas CD14, CD34,
and CD45 (negative markers of BM-MSCs) were expressed in
less than 1% of all cells (Fig. 1A). Therefore, the BM-MSCs
had successfully differentiated into osteocytes (Fig. 1B) and ad-
ipocytes (Fig. 1C).
Treatment With BM-MSCs Infected With Decorin-
Expressing Adenovirus Reverses the Histological
Changes and Biochemical Parameters of
Hepatic Fibrosis
Decorin expression was monitored by immunofluorescence
staining after the injection of DCN-MSCs into the fibrotic
rat livers. As expected, decorin was detected only in the
Figure 4. Bonemarrow-derivedmesenchymal stem cells infected with decorin-expressing adenovirus suppress hepatic fibrosis. (A, B):mRNA
expression levels of collagen-1 (A)anda-SMA (B). (C,D):Representativewesternblot fora-SMA (C)and its densitometric analysis (D). Values are
expressed as means6 SDs. p, p, .05, pp, p, .01. (E): Immunofluorescence staining of a-SMA in liver tissue. The expression of a-SMA in the
DCN-MSC-treatedgroup (G4)was significantly decreased comparedwith theuntreated cirrhotic group (G2) and theCA-MSC-treated group (G3).
Nuclei were stained with DAPI. Merged immunofluorescence images of a-SMA (green) and DAPI (blue) are shown. Scale bar = 75 mm. Abbre-
viations: CA-MSC, control adenovirus-infected mesenchymal stem cell; DAPI, 49,6-diamidino-2-phenylindole; DCN-MSC, decorin-expressing
adenovirus-infected bone marrow-derived mesenchymal stem cell; mRNA, messenger RNA; a-SMA, a-smooth muscle actin.
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DCN-MSC-treated group, and not in the CA-MSC-treated group
(Fig. 2B).
The histological changes of hepatic fibrosis were evaluated
by H&E and MTC staining (Fig. 2C). The Laennec fibrosis scores
revealed detailed individual changes within the cirrhotic tissue
(4A–4C, supplemental online Table 1). In the untreated cirrhotic
group, the liver sections exhibited strong H&E and MTC stain-
ing, revealing definite cirrhosis (stage 4 fibrosis) with regener-
ating nodules and fibrous septae. Treatment with CA-MSCs has
been shown to elicit protective effects against fibrotic changes,
a finding that is consistent with our results using autologous
BM-MSCs without genetic modification [6, 8]. The CA-MSC-
treated group had a significantly lower mean score compared
with the untreated cirrhotic group (Table 1). The degree of fi-
brosis was reduced in the DCN-MSC-treated group compared
with the CA-MSC-treated group, demonstrating the additional
antifibrotic actions of decorin (Fig. 2C and Table 1). These re-
sults were further confirmed by Picrosirius red staining to esti-
mate the collagen amount in each sample (Fig. 2C). The relative
proportions of the Picrosirius red-stained collagen areas were
determined by using image analysis software. The percentages
of the collagen areas were 17.36 8.65; 6.866 2.35; and 3.956
1.73 (p , .01) in the untreated cirrhotic group (G2), the CA-
MSC-treated group (G3), and the DCN-MSC-treated group
(G4), respectively (p , .01; Fig. 2D). The levels of hydroxypro-
line (mg/g) in liver tissue were 6.06 6 1.56; 50.23 6 5.13;
20.16 6 4.7; and 12.03 6 2.19 (p , .01) in the sham control
group (G1), G2, G3, and G4, respectively (Fig. 2E). Compared
with the untreated cirrhotic group, the DCN-MSC-treated
group exhibited significantly reduced collagen and lower he-
patic hydroxyproline content.
The serum levels of ALT, AST, and total bilirubin were signif-
icantly increased in the TAA-induced cirrhosis group (G2) com-
paredwith G1 (p, .01; Fig. 3A–3C). Treatmentwith DCN-MSCs
(G4) markedly reduced the ALT, AST, and bilirubin levels com-
paredwith G2 (p, .01). In addition, the serum level of albumin
was increased in G4 compared with G2 (p, .01; Fig. 3D). These
changes were all greater upon treatment with DCN-MSCs com-
pared with treatment with CA-MSCs, demonstrating the pro-
tective effects of decorin against hepatic fibrosis and liver
injury.
BM-MSCs InfectedWith Decorin-Expressing Adenovirus
Suppress Hepatic Fibrosis by Inhibiting TGF-b Signaling
The effects of decorin on the expression of collagen-1 and
a-SMA in liver tissue were evaluated by quantitative real-
time PCR andWestern blot analysis. The relative transcript lev-
els of collagen-1 were 16 0.25; 10.956 3.13; 4.446 2.18; and
2.96 6 1.84 (p , .01) in G1, G2, G3, and G4, respectively (Fig.
4A). The relative mRNA levels of a-SMA were 16 0.31; 8.226
3.23; 3.79 6 1.29; and 2.01 6 0.66 (p , .01), whereas the
a-SMA protein levels were 1 6 0.08; 2.23 6 0.23; 1.33 6
0.17; and 1.17 6 0.08 (p, .01) in G1, G2, G3, and G4, respec-
tively (Fig. 4B–4D). The antifibrogenic effects of DCN-MSCs (G4)
were consistently higher than those of CA-MSCs (G3). We also
observed the expression of a-SMA in the untreated cirrhotic
liver group (G2) by immunofluorescence and found that a-SMA
was expressed at significantly higher levels compared with G1.
However, treatment with DCN-MSCs abolished a-SMA upregula-
tion in livers from rats with TAA-induced cirrhosis (Fig. 4E).
These results suggest that adenoviral-mediated overexpression
of decorin in BM-MSCs effectively prevents fibrotic changes in
an animal model of cirrhosis.
We next investigated whether DCN-MSC-mediated pro-
tection against hepatic fibrosis involves TGF-b signaling. To
this end, the levels of TGF-b1 expression in liver tissue from
each of the groups were determined by quantitative PCR
and Western blot analysis. The relative mRNA levels of TGF-
b1 were 1 6 0.25; 4.11 6 0.95; 2.09 6 0.59; and 1.45 6
0.42 (p , .01) in G1, G2, G3, and G4, respectively (Fig. 5A).
Similarly, the relative protein levels of TGF-b1 were 1 6
0.09; 2.33 6 0.19; 1.59 6 0.18; and 1.31 6 0.07 (p , .01)
in G1, G2, G3, and G4, respectively (Fig. 5B, 5C). These results
reveal that DCN-MSCs prevent TGF-b1 upregulation in the cir-
rhotic liver, which is important because TGF-b1 can act in both
autocrine and paracrine manners. Furthermore, we observed
that DCN-MSC treatment significantly decreased the phos-
phorylation of Smad3, which acts downstream of TGF-b re-
ceptor activation. The normalized levels of phosphorylated
Smad3 were 1 6 0.26; 2.74 6 0.29; 2.07 6 0.21; and 1.5 6
0.12 (p , .01) in G1, G2, G3, and G4, respectively (Fig. 5B,
5D). We hypothesize that decorin-expressing MSCs protect
against hepatic fibrosis by efficiently blocking TGF-b medi-
ated responses. However, it remains to be established whether
the antifibrotic effect of DCN-MSCs is due to liberated decorin or
another factor.
Decorin-Mediated Regulation of TGF-b1/Smad
Signaling in HSCs
To investigate the mechanism by which decorin blocks TGF-b1/
Smad signaling, we infected HSCs with decorin-expressing
Figure 5. Bone marrow-derived mesenchymal stem cells infected
with decorin-expressing adenovirus ameliorate hepatic fibrosis by
inhibiting TGF-b signaling. (A): mRNA expression levels of TGF-b1.
(B–D): Representative Western blot (B) and densitometric analysis
for TGF-b1 (C) and phospho-Smad3 (D). Values are expressed as
means 6 SDs. pp, p , .01. Abbreviation: mRNA, messenger RNA;
TGF-b1, transforming growth factor-b1.
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adenovirus. In parallel, we also incubated HSCs with conditioned
medium from cultured DCN-MSCs. The protein levels ofa‐SMA
and phosphorylated Smad3 in these HSCs were assessed
by Western blot analysis (Fig. 6). Infection with decorin-
expressing adenovirus and exposure to DCN-MSC culture me-
dium both inhibited TGF-b1-induced upregulation of a-SMA.
Moreover, phosphorylation of Smad3 by exogenous TGF-b1
was markedly reduced by adenovirus-mediated delivery of
decorin into HSCs. The same effect was observed using condi-
tionedmedium fromdecorin-overexpressingMSCs (Fig. 6). These
data indicate that the extracellular actions of liberated decorin
are directly responsible for the DCN-MSC-mediated suppression
of TGF-b/Smad signaling.
DISCUSSION
In this study, we found that BM-MSCs infected with decorin-
expressing adenovirus exert therapeutic effects on hepatic
fibrosis in a rat model of TAA-induced cirrhosis. We also in-
vestigated the mechanism by which DCN-MSC treatment ame-
liorates fibrotic changes. Themajor findings of this study are as
follows: (a) direct injection of DCN-MSCs into rat livers after
TAA-mediated induction of cirrhosis protected against patho-
genic fibrosis; (b) DCN-MSC treatment recovered the impaired
liver function in our animal model of cirrhosis; (c) DCN-MSCs
inhibited TGF-b1 synthesis, Smad phosphorylation, and ex-
pression of collagen anda-SMA in the cirrhotic liver; and (d) in-
fection of HSCs with decorin-expressing adenovirus and
exposure to DCN-MSC-conditioned medium both blocked
Smad phosphorylation and a-SMA upregulation by exogenous
TGF-b1.
Recently, stem cell-based therapy has been proposed as a
promising alternative approach for treating liver disease [24,
25]. Several studies have suggested that BM-MSCs exert thera-
peutic benefits in the context of hepatic fibrosis and cirrhosis
[26, 27].
Decorin, a natural inhibitor of TGF-b1, is a small leucine-rich
proteoglycan that bindswith high affinity to TGF-b1 and prevents
its interaction with profibrotic receptors. In addition, decorin
regulates the production of extracellular matrix components,
inhibitors of collagen fibril maturation, and stimulators of col-
lagenase. Therefore, the administration of decorin has been
explored as a potential antifibrotic therapy in experimental
kidney [28], lung [29], and human corneal fibroblast models
[30]. However, the use of adenoviruses in targeted gene deliv-
ery is limited by their promiscuous native tropism,which allows
the virus to infect a broad range of cells and tissues [17]. Hence,
to improve the safety and efficacy of adenoviral-mediated gene
therapy and identify the optimal therapeutic modality for
hepatic fibrosis, efficient delivery vehicles for decorin are
required.
We hypothesized that a combination treatment consisting
of BM-MSCs and decorin would yield greater liver function im-
provement after the development of hepatic fibrosis compared
with treatment with BM-MSCs alone. Through histological
H&E, MTC, and Picrosirius red staining, we demonstrated
that administration of decorin-overexpressing MSCs resulted
in dramatic improvements in hepatic fibrosis compared with
the untreated cirrhotic group. It was particularly noteworthy
that DCN-MSCs exerted significantly more potent preventive
effects on hepatic fibrosis compared with MSCs infected with
mock adenovirus, implying that the effects of decorin andMSCs
are synergistic.
In this study, we used the new Laennec fibrosis scoring
system because it enables finer classification of F4 cirrhosis.
This classification approach is desirable because the severity
of cirrhosis exhibits clear histological variability. Further-
more, cirrhosis does not always develop in a linear manner.
The development of cirrhosis can arrest or even regress over
time if its root cause is removed and/or with modern antifi-
brotic treatment. According to the Laennec fibrosis scoring
system, histological improvement from hepatic fibrosis
was detected most strongly after DCN-MSC treatment (p ,
.01). These findings were supported by immunohistochemis-
try, Picrosirius red staining, and hepatic hydroxyproline con-
tent analyses.
TGF-b1 has been suggested to be a keymediator for hepatic
fibrosis progression [31, 32]. The fibrogenic functions of TGF-
b1, such as collagen synthesis, are mediated by the canonical
Smad pathway via activation of transmembrane TGF-b
Figure6. Effects of decorinonTGF-b/Smadsignaling inHSCs.Westernblot analysis of the levels ofa-SMAandphospho-Smad3 in immortalized
HSCs. (A): TGF-b1-induced changes after infection of HSCs with control adenovirus were compared with those after infection with decorin-
expressing adenovirus. (B): Analysis of the effects of bone marrow-derived mesenchymal stem cell-conditioned medium harvested from cells
infected with control adenovirus versus decorin-expressing adenovirus. Abbreviations: CA-MSCs, control adenovirus-infected mesenchymal
stem cells; DCN-MSCs, decorin-expressing adenovirus-infected bone marrow-derived mesenchymal stem cells; HSCs, hepatic stellate cells;
a-SMA, a-smooth muscle actin; TGF-b1, transforming growth factor-b1.
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receptors [1, 32]. Therefore, the TGF-b signaling pathway is
considered to be an attractive therapeutic target for hepatic
fibrosis treatment [1, 33, 34]. We observed significant upregu-
lation of TGF-b1 and phosphorylated Smad3 in cirrhotic rat liv-
ers, both of which were blocked by DCN-MSC treatment.
Moreover, decorin inhibited Smad3 phosphorylation in HSCs
upon exogenous TGF-b1 stimulation. This finding demon-
strates that decorin directly inhibits TGF-b/Smad signaling,
in addition to reducing TGF-b1 release. It is intriguing that
DCN-MSC-conditioned medium also blocked Smad signaling
and a-SMA synthesis, both of which were observed upon over-
expression of decorin in HSCs (Fig. 6). These results clearly
illustrate that the liberation of decorin from DCN-MSCs con-
tributes to their therapeutic effects against hepatic fibrosis
progression.
Here we showed that administration of DCN-MSCs into the
cirrhotic liver ameliorates hepatic fibrosis and that BM-MSCs
and decorin act in a synergisticmanner. To the best of our knowl-
edge, this concept is completely novel. However, the clinical
application of our approach is somewhat limited because the
safety of adenoviruses as vectors for gene therapy has not yet
been well established in humans. Further studies are necessary
to determine whether our approach is clinically viable. Never-
theless, our study clearly demonstrates that DCN-MSCs exert
therapeutic effects, a finding that has the potential to impact
new therapeutic approaches for treating patients with intracta-
ble cirrhosis.
CONCLUSION
These findings demonstrated that combination treatment con-
sisting of BM-MSCs and decorin strongly inhibited the progres-
sion of TAA-induced hepatic fibrosis in rats, compared with
BM-MSCs alone. Therefore, treatment with BM-MSCs infected
with decorin-expressing adenovirus could constitute a novel
and efficient therapeutic approach for patients with intractable
cirrhosis.
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